Germany· DE-A57-74ce166468f70011
Recombinate
A octocog alfa product containing octocog alfa, registered in Germany by Takeda Gmbh. The same ATC class is registered in 3 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Octocog alfa is registered in 3 of 19 countries.
Countries holding a registration under ATC B02BD28 (octocog alfa), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 1 of them publish a price we can compare per daily dose
Octocog alfa · ATC B02BD28
3 / 19 countries
- Franceprice
- Germany
- United Kingdom
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Octocog Alfa
- Manufacturer
- Takeda Gmbh
- Country
- Germany (DE)
- ATC code
- B02BD28
- ATC class
- Octocog alfa
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for octocog alfa.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Octocog alfa · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Octocog alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAdvate 1000 IUTakeda Manufacturing Austria
- CzechiaADVATETakeda Manufacturing Austria AG, Vídeň
- SpainADVATE 1.000 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLETakeda Manufacturing Austria Ag
- FinlandAdvateAbacus Medicine A/S
- United KingdomAdvate 1,000unit powder and solvent for solution for injection vialsTakeda UK Ltd
- IrelandAdvate 1000 IU/2 ml powder and solvent for solution for injectionTakeda Manufacturing Austria AG
- NetherlandsAdvate 1000 IU, poeder en oplosmiddel voor oplossing voor injectie 200 IU/mlTakeda Manufacturing Austria AG
- ItalyADVATE*1 flaconcino EV 1.000 Unita' Internazionali + 1 flaconcino solv 2 ml preassemblati con dispositivo per ricostituzioneTAKEDA MANUFACTURING AUS. AG
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Iceland · Advate, Kovaltry
- Italy · Recombinate
- Liechtenstein · Advate, Kovaltry
- Lithuania · Recombinate
- Netherlands · Recombinate
- Norway · Advate, Kovaltry
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/020f8122-a8d7-456e-9578-8f0adba4ec83 GET /v1/drugs/020f8122-a8d7-456e-9578-8f0adba4ec83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Octocog Alfa",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about octocog alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.